Mandate

Vinge has assisted Priveq in connection with the formation of Priveq Investment VII

June 04, 2024 Private Funds

Priveq, a leading Nordic lower mid-market growth and buyout investor, has closed its seventh fund, Priveq Investment VII, at SEK 3 billion. The fund’s first and final closing was significantly oversubscribed with strong backing from existing investors and substantial interest from new institutional investors.


The fund’s investor base consists of a diversified group of Nordic, European and North American investors including public and private pension funds, insurance companies, charitable foundations, endowments, public institutions, family offices and fund-of-funds.

Vinge has assisted Priveq as Swedish legal counsel in connection with the fund formation.

Vinge's team consisted of Mattias Schömer, Marcus Andersson, Nils Unckel, Anton Sjökvist, Emelie Svanberg, Tobias Onegård Karlsson, Semir Omerbasic, Emelie Zingmark, Helena Göransson, Nour Makie and Elias Kröger.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026